Shaimaa Soliman

Shaimaa Soliman

Auto-generated profile, based on publicly available information

Shaimaa Soliman

Department of Public Health and Community Medicine, Faculty of Medicine , Menoufia University (Shebin El-Kom) Egypt

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
HDHany M. Dabbous
Hany M. Dabbous
SASherief Abd-Elsalam
Sherief Abd-Elsalam
MEManal H. El-Sayed
Manal H. El-Sayed
ASAhmed F Sherief
Ahmed F Sherief
FEFatma F. S. Ebeid
Fatma F. S. Ebeid
MTMohamed Awad Tageldin
Mohamed Awad Tageldin

7 October 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
SASherief Abd-Elsalam
Sherief Abd-Elsalam
EEEslam Saber Esmail
Eslam Saber Esmail
MKMai Khalaf
Mai Khalaf
EAEhab Fawzy Abdo
Ehab Fawzy Abdo
MMMohammed A. Medhat
Mohammed A. Medhat
MAMohamed Alboraie
Mohamed Alboraie
The COVID-19 pandemic is showing an exponential growth, mandating an urgent need to develop an effective treatment. Indeed, to date, a well-established therapy is still lacking. We aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) added to standard care in patients with COVID-19. This was a multicenter, randomized controlled trial conducted at three major university hospitals in Egypt. One hundred ninety-four patients with confirmed diagnosis of COVID-19 were included in the study after signing informed consent. They were equally randomized into two arms: 97 patients administrated HCQ plus standard care (HCQ group) and 97 patients administered only standard care as a control arm (control group). The primary endpoints were recovery within 28 days, need for mechanical ventilation, or death. The two groups were matched for age and gender. There was no significant difference between them regarding any of the baseline characteristics or laboratory parameters. Four patients (4.1%) in the HCQ group and 5 (5.2%) patients in the control group needed mechanical ventilation (P = 0.75). The overall mortality did not differ between the two groups, as six patients (6.2%) died in the HCQ group and 5 (5.2%) died in the control group (P = 0.77). Univariate logistic regression analysis showed that HCQ treatment was not significantly associated with decreased mortality in COVID-19 patients. So, adding HCQ to standard care did not add significant benefit, did not decrease the need for ventilation, and did not reduce mortality rates in COVID-19 patients.

10 September 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
SASherief Abd-Elsalam
Sherief Abd-Elsalam
OAOssama Ashraf Ahmed
Ossama Ashraf Ahmed
NMNoha Mansour
Noha Mansour
DADoaa H. Abdelaziz
Doaa H. Abdelaziz
MSMarwa Salama
Marwa Salama
MEMohammed Elhendawy
Mohammed Elhendawy
To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with COVID-19. Patients were randomly assigned at a 1:1 ratio to receive either remdesivir (200 mg on the first day followed by 100 mg daily for the next 9 days intravenously infused over 30–60 minutes) in addition to standard care or standard care alone. The primary outcomes were the length of hospital stay and mortality rate. The need for mechanical ventilation was assessed as a secondary outcome. Two hundred patients (100 in each group) completed the study and were included in the final analysis. The remdesivir group showed a significantly lower median duration of hospital stay (10 days) than the control group (16 days; P < 0.001). Eleven of the patients in the remdesivir group needed mechanical ventilation compared with eight patients in the control group (P = 0.469). The mortality rate was comparable between the two groups (P = 0.602). Mortality was significantly associated with older age, elevated C-reactive protein levels, elevated D-dimer, and the need for mechanical ventilation (P = 0.039, 0.003, 0.001, and < 0.001 respectively). Remdesivir had a positive influence on length of hospital stay, but it had no mortality benefit in Egyptian patients with COVID-19. Its use, in addition to standard care including dexamethasone, should be considered, particularly in low- and middle-income countries when other effective options are scarce.

19 May 2020 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MEMohammed Elhendawy
Mohammed Elhendawy
EAEnas A. Abdul-Baki
Enas A. Abdul-Baki
SASherief Abd-Elsalam
Sherief Abd-Elsalam
MHMaha M. Hagras
Maha M. Hagras
AZAbdul-Aziz Zidan
Abdul-Aziz Zidan
SASaid Abdou
Said Abdou

1 March 2018 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
OAOssama A. Ahmed
Ossama A. Ahmed
MEMohamed A Elsebaey
Mohamed A Elsebaey
MFMohamed Hassan Ahmed Fouad
Mohamed Hassan Ahmed Fouad
HEHeba Elashry
Heba Elashry
AEAhmed I. Elshafie
Ahmed I. Elshafie
SASherief Abd-Elsalam
Sherief Abd-Elsalam
Background and aims: Treatment of hepatitis C virus (HCV) changed dramatically with the introduction of oral direct-acting antiviral drugs due to their high antiviral potency and safety profile. Sofosbuvir plus daclatasvir combination therapy was extensively investigated in HCV genotypes 1, 2, and 3, while published data regarding its real-life application in the treatment of genotype 4 is lacking. Therefore, we conducted this study to assess the outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection.
Patients and methods:
This prospective study included 300 Egyptian patients with chronic genotype 4 HCV, treated with sofosbuvir plus daclatasvir with or without ribavirin for 12–24 weeks. Primary outcome was the number of patients who achieved sustained virologic response (SVR12), and secondary outcome was the occurrence of adverse events. Results: A total of 92.67% of all patients achieved SVR12. SVR12 rates of 96.55% and 84.54% were reported in non-cirrhotic and cirrhotic patients, respectively. SVR12 in treatment-naïve and treatment-experienced patients were 94.12% and 87.01%, respectively. A total of 19.7% of patients experienced mild adverse events. Older age, cirrhosis, and low platelet count were the predictors of treatment non-response. Conclusion: Based on this multi-center prospective study, sofosbuvir plus daclatasvir with or without ribavirin for 12–24 weeks appears to have favorable outcomes in the treatment of genotype 4 HCV-infected Egyptian patients. Older age, cirrhosis, especially Child–Pugh class B, and low platelet count are independent risk factors of treatment non-response.

5 October 2017 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
SASherief Abd-Elsalam
Sherief Abd-Elsalam
MSMohamed Sharaf-Eldin
Mohamed Sharaf-Eldin
SSShaimaa Soliman
Shaimaa Soliman
AEAsem Elfert
Asem Elfert
RBRehab Badawi
Rehab Badawi
YAYoussef K. Ahmad
Youssef K. Ahmad